We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Tesamorelin (Egrifta; stabilized GHRH(1-44) analog)
A prescription growth-hormone-releasing-hormone (GHRH) analog — the drug Egrifta — FDA-approved in 2010 to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. Honest appraisal: unlike most peptides sold online, this one has REAL phase-3 randomized trials, but ALL of them are in ART-treated HIV patients with excess belly fat. The off-label 'anti-aging' / bodybuilding use that drives grey-market demand is NOT what the trials studied. It is a prescription injectable, not a dietary supplement; it raises IGF-1, its benefit fully reverses when you stop, and grey-market vials are unregulated.
Prescription medication — not a dietary supplement
Tesamorelin is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Tesamorelin doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2004–2026 with a typical study size of 806 participants.
Based on 30 studies · 2 meta-analyses · 21 RCTs · 867 total participants
Confidence
High confidenceBy outcome
An FDA-approved drug with multiple phase-3 RCTs and a meta-analysis showing real visceral- and liver-fat reduction, but all evidence is confined to HIV-associated lipodystrophy.
21 randomised trials
95% were about Tesamorelin in an audit of 21 of them
Every randomised or controlled trial of Tesamorelin indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
3 trials ongoing or recruiting · 14 completed on ClinicalTrials.gov
8 of the completed trials have posted results
Registered trials show research momentum for Tesamorelin, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Tesamorelin (brand name Egrifta; development code TH9507) is a synthetic, stabilized analog of human growth-hormone-releasing hormone — specifically a GHRH(1-44) peptide with an N-terminal modification that resists enzymatic degradation and extends its half-life relative to native GHRH.
It binds the pituitary GHRH receptor to stimulate the body's own pulsatile growth-hormone (GH) secretion, which in turn raises insulin-like growth factor 1 (IGF-1). The downstream GH/IGF-1 signal preferentially drives lipolysis of visceral (intra-abdominal) fat. It is given as a 2 mg once-daily subcutaneous injection.
Critically — and unlike the research peptides it is often grouped with — tesamorelin is an FDA-approved prescription drug (approved November 2010) with a genuine phase-3 evidence base.
Two multicenter, double-blind, placebo-controlled phase-3 RCTs (pooled n=806) showed visceral adipose tissue (VAT) fell about 15-18% over 26-52 weeks versus placebo in ART-treated HIV patients with excess abdominal fat, with improved triglycerides and body-image scores and without clinically meaningful glucose worsening.
A 52-week safety-extension RCT confirmed durability of the VAT reduction during continued treatment.
The drug also reduces liver fat: a Lancet HIV RCT (n=61) in HIV-associated NAFLD found a ~37% relative reduction in hepatic fat fraction over 12 months, and a JAMA RCT (n=50) showed reductions in both visceral and liver fat; a paired-biopsy transcriptomic substudy linked treatment to a favorable fibrosis-gene signature (while also flagging hepatocellular-carcinoma-related gene changes in both directions).
The most important honesty caveats: (1) ALL of the positive RCTs are in HIV patients — there is no phase-3 evidence for the 'anti-aging,' physique, or general-population fat-loss claims that drive most grey-market demand; (2) the benefit is entirely treatment-dependent — VAT reaccumulates within months of stopping; (3) a separate GHRH/tesamorelin RCT (n=152, Arch Neurol 2012) in older adults with mild cognitive impairment and healthy controls reported a favorable cognitive effect, but a more recent phase-2 open-label trial in HIV patients with abdominal obesity (n=73, 2025) found no clear neurocognitive benefit — so the cognition story is mixed and not an approved use; (4) it is a prescription injectable that raises IGF-1, carrying a theoretical neoplasia concern (contraindicated in active malignancy) and glucose/insulin effects; and (5) buying it outside a prescription means unregulated grey-market vials of unverified identity, purity and sterility.
Overall the evidence is Moderate — solid for its narrow approved visceral-fat indication, thin-to-absent for the popular off-label uses.
Tesamorelin is a stabilized GHRH(1-44) analog that binds and activates the growth-hormone-releasing-hormone receptor on pituitary somatotrophs, stimulating the body's own GH synthesis and release. An N-terminal modification slows enzymatic breakdown, giving it a longer half-life than native GHRH while preserving physiologic, pulsatile GH secretion.
By driving endogenous GH pulses, tesamorelin raises insulin-like growth factor 1 (IGF-1). In the phase-3 trials IGF-1 rose roughly 1.5- to 2-fold (about +48-65% in dose-ranging work) and stayed within or near the physiologic range. This IGF-1 rise is the surrogate marker of pharmacologic effect.
GH preferentially mobilizes intra-abdominal (visceral) fat. In ART-treated HIV patients with excess abdominal fat, tesamorelin selectively reduced visceral adipose tissue by CT while preserving subcutaneous fat — the basis for its FDA-approved indication. The same axis reduces ectopic liver fat.
How Tesamorelin works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Contraindicated in active malignancy; tesamorelin raises IGF-1, a theoretical proliferative concern. Decisions about prior-cancer history require oncology input.
Contraindicated in pregnancy; avoid in breastfeeding. GH/IGF-1 stimulation is inappropriate during pregnancy and developmental effects are unknown.
Use only under medical supervision with glucose monitoring — GH excess reduces insulin sensitivity and can raise glucose.
Off-label and outside the evidence base. The phase-3 RCTs were exclusively in ART-treated HIV patients with excess abdominal fat; benefit in other populations is unproven.
Growth hormone reduces insulin sensitivity and can raise blood glucose, so tesamorelin may blunt glucose-lowering therapy. Glucose should be monitored, especially in diabetes or impaired glucose tolerance — a transient early glucose rise was seen in the trials.
The GH/IGF-1 axis interacts with glucocorticoid metabolism; the label notes potential effects on cortisol-replacement dosing via 11β-HSD-1. Doses of concomitant cortisone/cortisol-replacement may need adjustment under medical supervision.
GH can modulate CYP-mediated metabolism; the label flags possible changes in CYP-substrate exposure. Relevant given the HIV-population context where antiretrovirals are co-administered — managed by the prescriber.
Tip: Rotate injection sites; the NAFLD RCT reported more localized injection-site complaints in the tesamorelin arm, none judged serious.
Tip: Typical of GH/IGF-1 stimulation; report persistent symptoms to the prescriber, who may dose-adjust or stop.
Tip: Monitor glucose/HbA1c; caution in diabetes or impaired glucose tolerance. Net changes were generally not clinically meaningful at 26-52 weeks but a transient early rise occurred.
Tip: Recognized GH-axis effects; report to prescriber.
Tip: Discontinue and seek care for rash, urticaria, or systemic hypersensitivity.
Tesamorelin has an evidence score of 5/10 — moderate evidence based on 30 indexed studies, including 1 meta-analysis. A prescription growth-hormone-releasing-hormone (GHRH) analog — the drug Egrifta — FDA-approved in 2010 to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. Honest appraisal: unlike most peptides sold online, this one has REAL phase-3 randomized trials, but ALL of them are in ART-treated HIV patients with excess belly fat. The off-label 'anti-aging' / bodybuilding use that drives grey-market demand is NOT what the trials studied. It is a prescription injectable, not a dietary supplement; it raises IGF-1, its benefit fully reverses when you stop, and grey-market vials are unregulated. Representative study: PMID 41545261.
Dosing for Tesamorelin: Approved regimen (Egrifta, HIV-associated lipodystrophy only): 2 mg once daily by subcutaneous injection. This is a prescription drug — the dose, indication and monitoring are set by a prescriber. The cognition RCT used a lower 1 mg/day. There is NO validated dose for off-label 'anti-aging' or physique use, and any such use is outside the evidence base. Individual needs vary, so check the right dose for you with a healthcare provider.
Timing is flexible for Tesamorelin — consistent daily use matters more than the time of day. The approved HIV-lipodystrophy regimen is 2 mg subcutaneously once daily, rotated injection site, independent of meals.
Tesamorelin should be used with caution — talk to a healthcare provider before taking it. Reported side effects include increased fasting glucose / reduced insulin sensitivity, hypersensitivity / injection-related reactions, injection-site reactions (erythema, pruritus, pain, irritation, swelling, bruising). How often they occur is not established for all of them. Use caution if any of these apply to you: Active malignancy — tesamorelin raises IGF-1, a theoretical proliferative/neoplasia concern; it is contraindicated in active cancer; Pregnancy — contraindicated; GH/IGF-1 stimulation is inappropriate in pregnancy; Disruption of the hypothalamic-pituitary axis (hypophysectomy, pituitary tumor/surgery/radiation, head irradiation) per the approved label.
Semaglutide
Too few graded studiesAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is a prescription drug, not a supplement, and is never auto-recommended.
Tirzepatide
Too few graded studiesAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a US FDA boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Liraglutide
Too few graded studiesAn FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. It is a prescription medicine, NOT a supplement, and is not auto-recommended.
Orforglipron
Too few graded studiesAn ORAL, non-peptide small-molecule GLP-1 receptor agonist for obesity, also studied in type 2 diabetes — the headline is the convenience of a once-daily pill (no injection, no cold chain, no food/water restrictions) delivering GLP-1-class glycemic and weight benefit. In the US, orforglipron is approved as Foundayo for long-term weight management in adults with obesity, or overweight with at least one weight-related condition, together with a reduced-calorie diet and increased physical activity. FDA approval was granted on 1 April 2026. An EMA list dated 5 October 2026 places orforglipron under evaluation. Honest appraisal: the phase-2 data are strong and the phase-3 read-outs (ATTAIN/ACHIEVE) are promising, but it has the full GLP-1-class side-effect burden (very common dose-dependent nausea/vomiting/diarrhea, higher discontinuation than injectables in some comparisons), the US label carries a boxed warning about thyroid C-cell tumours, and long-term outcomes are unsettled. It is NOT a dietary supplement.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 30 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research